const listdata = {
    asthma: [{
            catalog: "第一章",
            value: "哮喘疾病基础知识篇",
            list: [{
                    title: "哮喘的定义",
                    to: 1
                },
                {
                    title: "哮喘的流行病学",
                    to: 2
                },
                {
                    title: "哮喘的发病机制",
                    to: 3
                },
                {
                    title: "哮喘的诊断",
                    to: 4
                },
                {
                    title: "哮喘的评估",
                    to: 5
                },
                {
                    title: "哮喘的维持期治疗",
                    to: 6
                },
                {
                    title: "哮喘的急性发作期治疗",
                    to: 7
                },
            ]
        },
        {
            catalog: "第二章",
            value: "舒利迭®产品知识篇",
            list: [{
                    title: "舒利迭®产品基本信息",
                    to: 1
                },
                {
                    title: "舒利迭®准纳器方便易用，输出稳定",
                    to: 2
                },
                {
                    title: "舒利迭®哮喘治疗领域",
                    to: 3
                },
                {
                    title: "关键临床研究：",
                    to: 3
                },
                {
                    title: "- GOAL、",
                    to: 3
                },
                {
                    title: "- EXCEL、",
                    to: 4
                },
                {
                    title: "- CONCEPT、",
                    to: 5
                },
                {
                    title: "- LundBack 3年研究",
                    to: 6
                }
            ]
        },
        {
            catalog: "第三章",
            value: "舒利迭®成人哮喘|市场推广篇",
            list: [{
                    title: "舒利迭成人哮喘关键推广信息",
                    to: 1
                },
                {
                    title: "舒利迭成人哮喘市场策略",
                    to: 1
                },
                {
                    title: "舒利迭成人目标患者",
                    to: 2
                },
                {
                    title: "舒利迭成人哮喘目标科室",
                    to: 2
                },
                {
                    title: "客户分类及拜访策略",
                    to: 3
                },
            ]
        },
        {
            catalog: "第四章",
            value: "应对竞争产品篇",
            list: [{
                    title: "中国市场ICS/LABA产品",
                    to: 1
                },
                {
                    title: "信必可®关键研究解读",
                    to: 2
                },
                {
                    title: "- COSMOS",
                    to: 2
                },
                {
                    title: "- COMPASS",
                    to: 3
                },
                {
                    title: "- EuroSMART",
                    to: 4
                },
                {
                    title: "- SYGMA",
                    to: 5
                }
            ]
        },
        {
            catalog: "第五章",
            value: "APACT",
            list: [{
                    title: "信必可® SMART策略既能作为控制用药， 又能充当缓解用药",
                    to: 1
                },
                {
                    title: "信必可®治疗哮喘快速起效",
                    to: 2
                },
                {
                    title: "信必可®也是ICS/LABA联合制剂，同样也能抗炎",
                    to: 3
                },
                {
                    title: "GINA指南已经将 SMART治疗策略纳入推荐治疗方案，这就是说指南已经认可信必可®SMART策略可以达到与舒利迭®ACD策略同样的哮喘控制。",
                    to: 4
                },
                {
                    title: "SYGMA研究: 我听说新英兰杂志近期发表了一篇轻度哮喘患者按需使用信必可的最新数据，达到了研究的主要终点，对于那些轻度的哮喘患者无疑又多了一种治疗方案",
                    to: 5
                }
            ]
        },
        {
            catalog: "附录",
            value: "",
            list: [{
                    title: "哮喘控制的调查问卷",
                    to: 1
                },
                {
                    title: "- 1. ACT",
                    to: 1
                },
                {
                    title: "- 2.ACQ和ACQ-5",
                    to: 2
                },
                {
                    title: "- 3.AQLQ ",
                    to: 3
                },
                {
                    title: "- 4.ATAQ",
                    to: 4
                },
                {
                    title: "哮喘相关医学名词",
                    to: 5
                },
                {
                    title: "Q＆A",
                    to: 6
                },
                {
                    title: "舒利迭®关键产品安全性信息",
                    to: 7
                }
            ]
        }
    ],
    copd: [{
            catalog: "第一章",
            value: "慢阻肺疾病基础知识篇",
            list: [{
                    title: "慢阻肺的定义",
                    to: 1
                },
                {
                    title: "慢阻肺的流行病学",
                    to: 2
                },
                {
                    title: "慢阻肺的发病机制",
                    to: 3
                },
                {
                    title: "慢阻肺的诊断",
                    to: 4
                },
                {
                    title: "慢阻肺的评估",
                    to: 5
                },
                {
                    title: "慢阻肺稳定期治疗",
                    to: 6
                },
                {
                    title: "慢阻肺急性加重期治疗",
                    to: 7
                },
            ]
        },
        {
            catalog: "第二章",
            value: "舒利迭®产品知识篇",
            list: [{
                    title: "舒利迭®产品基本信息",
                    to: 1
                },
                {
                    title: "舒利迭®准纳器方便易用，输出稳定",
                    to: 2
                },
                {
                    title: "舒利迭®慢阻肺领域",
                    to: 3
                },
                {
                    title: "关键临床研究：",
                    to: 4
                },
                {
                    title: "BIOPSY研究",
                    to: 4
                },
                {
                    title: "TRISTAN研究",
                    to: 5
                },
                {
                    title: "TORCH研究",
                    to: 6
                },
                {
                    title: "中国注册临床研究",
                    to: 7
                },
                {
                    title: "INSPIRE研究",
                    to: 8
                },
                {
                    title: "TORCH事后分析",
                    to: 9
                }
            ]
        },
        {
            catalog: "第三章",
            value: "舒利迭®慢阻肺|市场推广篇",
            list: [{
                    title: "舒利迭慢阻肺关键推广信息",
                    to: 1
                },
                {
                    title: "舒利迭慢阻肺市场策略",
                    to: 1
                },
                {
                    title: "舒利迭目标患者",
                    to: 1
                },
                {
                    title: "舒利迭慢阻肺目标科室",
                    to: 2
                },
                {
                    title: "客户分类及拜访策略",
                    to: 2
                },
            ]
        },
        {
            catalog: "第四章",
            value: "应对竞争产品篇",
            list: [{
                    title: "中国市场ICS/LABA产品",
                    to: 1
                },
                {
                    title: "信必可®关键研究",
                    to: 2
                },
                {
                    title: "PATHOS研究",
                    to: 2
                },
                {
                    title: "SPEED研究",
                    to: 3
                },
            ]
        },
        {
            catalog: "第五章",
            value: "APACT",
            list: [{
                    title: "挑战1: TORCH研究的主要研究终点 是观察中重度COPD患者使用舒利迭® 3年与安慰剂组相比对全因死亡率的 影响。结果显示，与安慰剂组相比， 舒利迭®使全因死亡率降低17.5％， 但在统计学方面没有达到显著差异 （P＝0.052），所以我们认为舒利迭® 对COPD全因死亡率没有改善作用。",
                    to: 1
                },
                {
                    title: "挑战2:舒利迭®500中ICS的剂量大， 长期治疗COPD的过程中，肺炎发生的 风险会增加，我对此比较担心。",
                    to: 2
                },
                {
                    title: "挑战3:使用信必可®的患者与用舒利迭® 的患者相比，肺炎发生率较少。",
                    to: 3
                },
                {
                    title: "挑战4:使用信必可®的COPD患者与用 舒利迭®的COPD患者相比，急性加重 发生率较少。",
                    to: 4
                },
                {
                    title: "挑战5:即便在相同吸气流速（60L/min） 下，为什么准纳器®与都保®相比， 每吸输出的药粉剂量的变异范围更小， 输出稳定性更高？",
                    to: 5
                },
                {
                    title: "挑战6:不同吸气流速时，为什么 舒利迭®准纳器®与信必可®都保® 相比药物输出更稳",
                    to: 6
                },
                {
                    title: "挑战7:我的有些患者使用舒利迭® 效果不明显，而相对来说噻托溴铵 效果比较",
                    to: 7
                },
                {
                    title: "挑战8:治疗COPD仅需要使用茶碱 或万托林或异丙托溴铵改善患者症状 就可以",
                    to: 8
                },
                {
                    title: "挑战9: 2018 GOLD中，对绝大部分 患者推荐使用LAMA类药类（如B、 C、D），我们临床上就会考虑将 噻托溴铵作为大多数患者的基础治疗。 如果患者疗效不佳或还有较高的急性 加重风险，我们才会考虑选择 添加舒利迭®。",
                    to: 9
                },

            ]
        },
    ],
    gso: [{
            catalog: "第一章",
            value: "GSO销售拜访模型",
            list: [{
                    title: "1.	定义GSO",
                    to: 1
                },
                {
                    title: "2.	GSO销售拜访模型",
                    to: 2
                },
                {
                    title: "3.	GSO步骤和目的",
                    to: 3
                },
                {
                    title: "4.	GSO的3大驱动因素",
                    to: 4
                },
            ]
        },
        {
            catalog: "第二章",
            value: "Check List",
            list: [{
                    title: "1.	GSO演练观察项目",
                    to: 1
                },
                {
                    title: "2.	GSO Check List Demo",
                    to: 2
                },
                {
                    title: "3.	GSO Check List",
                    to: 3
                }
            ]
        },
        {
            catalog: "第三章",
            value: "GSO舒利迭标准拜访案例",
            list: [{
                    title: "1.	哮喘GSO拜访标准案例",
                    to: 1
                },
                {
                    title: "-较轻未控制",
                    to: 1
                },
                {
                    title: "-较重未控制",
                    to: 2
                },
                {
                    title: "-持续性咳嗽未控制",
                    to: 3
                },
                {
                    title: "2.	慢阻肺GSO拜访标准案例",
                    to: 4
                },
                {
                    title: "-有多次急性加重史或者一次急性加重住院史",
                    to: 4
                },
                {
                    title: "-有过急性加重史，但主诉只强调症状多",
                    to: 5
                },
            ]
        }
    ],
}
export default listdata;